The reduction in the price target from $35 to $19 by a reputable analyst firm like HC Wainwright & Co. could lead to a negative short-term impact on Nurix Therapeutics' stock price. This adjustment reflects a significant change in the expected future performance of the company, potentially influencing investor sentiment and stock valuation.